Diagnosis and Management of Rheumatoid Arthritis
TUESDAY, March 19, 2019
12:15pm—Hope Conference Center
DIAGNOSIS AND MANAGEMENT OF RHEUMATOID ARTHRITIS
PENG FAN, MD
CLINICAL PROFESSOR OF MEDICINE, DIVISION OF RHEUMATOLOGY
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
PLANNER/MODERATOR:
Nilesh Desai, MD, Department of Medicine liaison to the Medical Education Committee, PSJMC
FACULTY/PLANNER DISCLOSURES:
It is our policy to ensure that planners, faculty and content are independent of commercial bias. Dr. Desai states he has no financial arrangements with any commercial company to disclose. Dr. Fan discloses he is on the Speakers Bureau for Amgen, Novartis, Pfizer, Sanofi, Genzyme, Abbrie, Radius, Regeneron. It is our policy to review presentations ahead of time in order to resolve any potential conflicts of interest. No conflicts were identified in the review of today’s presentation.
Disclosures for members of the Medical Education Committee may be found at the CME sign-in desk and on the CME website at
www.providencecme.org.
Click Here For Learning Objectives
Release Date: 5-15-19
Review Date: 5/22
Termination Date:
This activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.
|
|
3/19/2019
|
|
Peng
Fan
|
|
Presenter
|
|
Hope Conference Center
|
|
|
Complete Video Confirmation
In order to complete the evaluation, you must log in.
|
|
Tinnitus
|
|
THURSDAY, November 21, 2019
12:15pm— Hope Conference Center
TINNITUS: CLINICAL MANAGEMENT, IMAGING, AND TREATMENT
ROBERT DARFLINGER, MD, INTERVENTIONAL RADIOLOGY, PSJMC
WARREN LINE, JR., MD, DEPARTMENT OF SURGERY, PSJMC
MODERATOR:
Michael Marvi, MD, Department of Medicine, PSJMC
FACULTY/PLANNER DISCLOSURES:
It is our policy to ensure that planners, faculty and content are independent of commercial bias. Drs. Line and Darflinger state they have no financial relationships with any commercial company to disclose.
Disclosures for members of the Medical Education Committee may be found at the CME sign-in desk and on the CME website at
www.providencecme.org.
Click Here For Learning Objectives
Release Date: 12-06-19
Review Date: 12/22
Termination Date:
This activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.
|
|
|
|
|
|
Stroke Prevention after ICH
|
|
TUESDAY, November 12, 2019
12:15pm – Hope Conference Center
SECONDARY STROKE PREVENTION
NERSES SANOSSIAN, MD, FAHA
ASSOC. PROFESSOR (CLINICAL SCHOLAR); DIR., NEUROCRITICAL CARE & STROKE
DEPARTMENT OF NEUROLOGY, USC
MODERATOR: Lin LeMay, MD, Chair, Neurology Section, PSJMC
FACULTY/PLANNER DISCLOSURES:
It is our policy to ensure that planners, faculty and content are independent of commercial bias. Dr. Sanossian states he is on the Speaker’s Bureau for Genentech, consults on the Clinical Events Committees for Clinical Trials for Medtronic and has received grant funding from Diffusion Pharma. It is our policy to review presentations ahead of time in order to resolve any potential conflicts of interest. No conflicts were identified in the review of today’s presentation.
Disclosures for members of the Medical Education Committee may be found at the CME sign-in desk and on the CME website
at
www.providencecme.org.
Click Here For Learning Objectives
Release Date: 12-03-19
Review Date: 12/22
Termination Date:
This activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.
|
|
|
|
|
|
SJMC "Active Threat" Considerations
|
|
TUESDAY, July 16, 2019
12:15pm – Hope Conference Center
“ACTIVE THREAT” CONSIDERATIONS: DEFINE, PREPARE, RESPOND
LIEUTENANT ADAM CORNILS
BURBANK POLICE DEPARTMENT
PLANNER/MODERATOR: Connie Lackey, RN; Director, Emergency
Preparedness/Safety/Security, PSJMC, PHCMC, PTMC
FACULTY/PLANNER DISCLOSURES:
It is our policy to ensure that planners, faculty and content are independent of commercial bias. Ms. Lackey and Lt. Cornils state they have no financial arrangements with any commercial company to disclose.
Disclosures for members of the Medical Education Committee may be found at the CME sign-in desk and on the CME website at
www.providencecme.org.
Click Here For Learning Objectives
Release Date: 9-24-19
Review Date: 9/22
Termination Date:
This activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.
|
|
|
|
|